Printer Friendly

Memantine may have value against alcoholism.

SCOTTSDALE, ARIZ. -- Memantine, the Alzheimer's drug, could have a new use: alcohol-dependence treatment.

In a small pilot study of 16 patients who met Diagnostic and Statistical Manual criteria for alcohol dependence and who were treated with memantine for 8 weeks, drinking behavior declined, Dr. Albert J. Arias said in a poster presentation at the annual meeting of the American Academy of Addiction Psychiatry.

The mean number of drinking days reported by the patients declined 18% during the 8 weeks of the study, compared with the weeks before treatment. The mean number of heavy drinking days declined 22%, and the mean number of drinks per drinking day declined by two.

Moreover, all except three patients had a decrease in the number of drinks per drinking day, all except four had a decrease in drinking days, and all except five had a decrease in heavy drinking days.

The trial was not definitive, since there were no control subjects. The patients also received seven sessions of counseling and were enrolled because they had a stated desire to reduce their alcohol intake.

The investigators would have liked to have seen a bigger impact, said Dr. Arias of the Alcohol Research Center at the University of Connecticut, Farmington, in an interview. "Our impression is that we significantly underdosed," he said.

The dose used started at 5 mg/day and was titrated up by 5 mg/week to 20 mg/day. All but 1 of the 16 patients completed the study. That patient complained of fatigue, the most common adverse effect. A dosage reduction did not alleviate his fatigue. Still, overall, the drug was well tolerated. The other patients who initially experienced fatigue reported that their fatigue diminished over time, Dr. Arias said.

Some of the patients reported that the drug seemed to produce a rapid improvement in cognitive functioning and sleep.

A dose of 60-80 mg/day, which has been shown to be tolerable, might be more effective. At Columbia University, New York, another research group has already begun a trial using a dose of 60 mg/day, he added.

Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist, and NMDA receptor function has been implicated in alcohol dependence. In human laboratory studies, it reduced alcohol craving.

BY TIMOTHY F. KIRN

Sacramento Bureau
COPYRIGHT 2006 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Kirn, Timothy F.
Publication:Internal Medicine News
Geographic Code:1USA
Date:Mar 1, 2006
Words:376
Previous Article:Self-management key to beating obesity in youth.
Next Article:Alcohol dependence.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters